Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Eleni Chantzoura"'
Autor:
Yury Patskovsky, Aswin Natarajan, Larysa Patskovska, Samantha Nyovanie, Bishnu Joshi, Benjamin Morin, Christine Brittsan, Olivia Huber, Samuel Gordon, Xavier Michelet, Florian Schmitzberger, Robert B. Stein, Mark A. Findeis, Andy Hurwitz, Marc Van Dijk, Eleni Chantzoura, Alvaro S. Yague, Daniel Pollack Smith, Jennifer S. Buell, Dennis Underwood, Michelle Krogsgaard
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract Altered protein phosphorylation in cancer cells often leads to surface presentation of phosphopeptide neoantigens. However, their role in cancer immunogenicity remains unclear. Here we describe a mechanism by which an HLA-B*0702-specific acu
Externí odkaz:
https://doaj.org/article/90c3efa5a9bc4657b99b525a37d24797
Autor:
Yury Patskovsky, Aswin Natarajan, Larysa Patskovska, Samantha Nyovanie, Bishnu Joshi, Benjamin Morin, Christine Brittsan, Olivia Huber, Samuel Gordon, Xavier Michelet, Florian Schmitzberger, Robert B. Stein, Mark A. Findeis, Andy Hurwitz, Marc Van Dijk, Eleni Chantzoura, Alvaro S. Yague, Daniel Pollack Smith, Jennifer S. Buell, Dennis Underwood, Michelle Krogsgaard
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/728e056355c04efaad198cf4c8ba6b89
Autor:
Xavier Michelet, Eleni Chantzoura, Marc Van Dijk, Deborah Wright, Efrat Altman-Sharoni, Martyna Popis, Reed Masakyan, Paul Ibbett, Moira Pinzan Rossi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/805d87aa40c64320b435d1a7f58a43e6
Autor:
Burcu Yigit, Xavier Michelet, Shalu Kharkwal, Eleni Chantzoura, Jan Bergmann, Alvaro Sebastian Yague, Simon Yue, Darrian Moskowitz, Benjamin Wolf, Mark Exley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/4ab76f12bd9144fb9d338dd4263b7af5
Autor:
Eleni Chantzoura, Stavroula Skylaki, Sergio Menendez, Shin-Il Kim, Anna Johnsson, Sten Linnarsson, Knut Woltjen, Ian Chambers, Keisuke Kaji
Publikováno v:
Stem Cell Reports, Vol 5, Iss 3, Pp 350-364 (2015)
Since the first generation of induced pluripotent stem cells (iPSCs), several reprogramming systems have been used to study its molecular mechanisms. However, the system of choice largely affects the reprogramming efficiency, influencing our view on
Externí odkaz:
https://doaj.org/article/f0d7b17401954c348fd86c457e67511b
Autor:
Eleni Chantzoura, Efrat Altman Sharoni, Reed Masakayan, Martyna Popis, Darrian Moskowitz, Paul Ibbett, Sapana Kadel, Moira Pinzan Rossi, Deborah Wright, Burcu Yigit, Olivier Le Tonqueze, Xavier Michelet, Marc Van Dijk
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Xavier Michelet, Martyna Popis, Shannon Boi, Magda Niedzielska, Reed Masakayan, Efrat Altman Sharoni, Paul Ibbett, Deborah Wright, Barbara Barbara Kalinowska, Justin Keith, Bishnu Joshi, Moira Pinzan Rossi, Rachel Smith, Burcu Yigit, Olivier Le Tonqueze, Eleni Chantzoura, Marc Van Dijk
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Eleni Chantzoura, Xavier Michelet, Dhan Chand, Jan Bergmann, Mark A. Exley, Darrian Moskowitz, Marc Van Dijk, Simon Yue, Alvaro Sebastian Yague, Shalu Sharma Kharkwal, Burcu Yigit, Benjamin Wolf
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Harnessing both the innate and adaptive immune system could increase the efficiency of current cancer immunotherapies and promote durable anti-tumor immunity. Invariant natural killer T (iNKT) cells are innate-like lymphocytes that bridge
Publikováno v:
In Free Radical Biology and Medicine 1 January 2008 44(1):91-98
Autor:
Paul Ibbett, Eleni Chantzoura, Martyna Popis, Deborah Wright, Marc van Dijk, Moira Pinzan Rossi, Efrat Altman-Sharoni, Xavier Michelet, Reed Masakyan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundChimeric antigen receptor (CAR) T cell therapy has shown outstanding benefit in hematological malignancies with three autologous CAR-T therapies commercially available and several in clinical development. The use of autologous T cells to ma